Cardiovascular Drugs and Therapy

Aims & Scope

Cardiovascular Drugs and Therapy is dedicated to the development of cardiovascular drug, device, and cell therapy from bench to bedside. The journals takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focuses on developments that include: hyperlipidemia, diabetes and other cardiometabolic conditions, atherosclerosis, ischemic syndromes, heart failure, cardiomyopathies, valvular heart disease, and arrhythmias. These include mechanisms of action and signaling pathways, their potential for new drug development, novel indications for older drugs, genetic approach to treatment, and new directions in device and cell therapy, interventional and structural heart disease, and cardiac and vascular surgery, as well as their guideline-based utilization in real-world patient populations. Authoritative source for researchers and investigators aiming for breakthrough research as well as cardiologists seeking to best serve their patients. Focuses on developments in treatment of various cardiovascular conditions.

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Subject Classification